Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, signaling a new site build or update for the study details page.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page’s revision label was updated to v3.6.5, indicating a new maintenance release of the study page. No study details or content appear to have changed as part of this update.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This represents a minor update to the page's revision history rather than changes to the study details or user-facing content.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page revision tag was updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a small housekeeping update to the page's metadata rather than a change to the study details.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a minor maintenance update to the page version without altering study details.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page's Study Documents section and several blocks listing study locations, investigators, and identifiers have been removed. This reduces visibility of critical trial materials and contact information, affecting the ability to review and engage with the study record.SummaryDifference19%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.